Pharmacokinetics vs Pharmacodynamics: Pharmacology Basics

Drug interactions can be classified as pharmacodynamic or pharmacokinetic. Pharmacodynamic interactions occur when the effect of a drug is changed by another substance acting at the same place, resulting in additive effects (total effect equals sum of individual effects), synergistic effects (total effect greater than sum), or antagonistic effects (action diminished). Pharmacokinetic interactions occur when the concentration of a drug changes in the body due to altered clearance or peak levels, and are complex and difficult to predict because they involve unrelated pharmacologic actions.

Drug interactions occur when one drug affects another's action, classified as pharmacokinetic or pharmacodynamic. Pharmacokinetic interactions affect absorption, distribution, metabolism, or excretion: (1) Absorption - one drug may bind another in the GI tract; (2) Distribution - competition for plasma protein binding sites increases free drug concentration; (3) Metabolism - enzyme inhibition or induction alters drug clearance; (4) Excretion - one drug may affect elimination of another. Pharmacodynamic interactions affect drug effects: additive (1+1=2), synergistic (1+1>2), or antagonistic (1+1<2). Understanding interactions is crucial for safe prescribing to prevent treatment failure or toxicity.

Drug interactions are pharmacodynamic (linked to mechanism of action, modifying effects without changing blood concentration) or pharmacokinetic (modifying drug fate in the organism, changing blood concentration). Pharmacodynamic interactions include synergy (addition of effects, e.g., sulfamethoxazole-trimethoprim produces bactericidal effect) and antagonism (opposition of effects, e.g., metoclopramide prevents levodopa binding). Pharmacokinetic interactions occur at absorption, distribution, metabolism, or excretion stages. The most clinically significant occur at absorption and metabolism, potentially causing increased drug concentrations or treatment inefficacy.

Pharmacokinetic interactions affect drug handling through four key processes. Absorption interactions occur when drugs alter gastric emptying (slowing it reduces absorption rate) or form insoluble complexes (iron tablets with antacids). Distribution interactions involve competition for plasma protein binding sites, displacing drugs and increasing free drug concentration. Metabolism interactions center on cytochrome P450 enzymes: inducers (like rifampicin) accelerate drug breakdown, while inhibitors (like cimetidine) cause drug accumulation. These mechanisms determine drug concentrations in the bloodstream and therapeutic effectiveness.

Drug interactions occur through pharmacodynamic and pharmacokinetic mechanisms. Pharmacodynamic interactions include competitive antagonism (drugs competing for same receptor), non-competitive antagonism (drugs acting on different receptors with opposing effects), additive interactions (effects summing together), and synergistic interactions (combined effect greater than sum). Pharmacokinetic interactions involve absorption (ionization, pH, precipitation, gastric emptying, microbiota), distribution (protein binding, volume of distribution), metabolism (hepatic enzyme induction/inhibition), and excretion (urinary pH, active transport competition). Examples include naloxone displacing opioids, thiazide-betablockers additively lowering BP, trimethoprim-sulfamethoxazole synergistically inhibiting folic acid synthesis, and rifampicin increasing paracetamol toxicity.

The dose-response relationship describes how drug concentration in plasma progressively increases and correspondingly, its effects on the body also increase. Two key properties define this relationship: potency and efficacy. Potency refers to the amount of drug required to produce a specific effect, typically measured as the dose needed to achieve 50% of the maximum effect (EC50). A drug with high potency requires a smaller dose to produce the same effect. Efficacy (Emax) represents the maximum effect a drug can produce, which is 100% of the response. Once all receptors are occupied by the drug, the effect cannot increase further regardless of additional drug concentration. Potency is directly related to a drug's affinity for its receptor - drugs with higher affinity bind more readily and show higher potency. Changes in potency shift the dose-response curve along the x-axis: increased potency shifts the curve left (lower doses needed), while decreased potency shifts it right. Efficacy is determined by the number of drug-receptor complexes formed and the intrinsic activity of the drug-receptor complex. Drugs are classified based on intrinsic activity into agonists (which activate receptors) and antagonists (which block receptors). Agonists are further classified as full agonists (intrinsic activity = 1, produce 100% of Emax), partial agonists (intrinsic activity between 0 and 1, produce submaximal response), and inverse agonists (intrinsic activity < 0, produce response opposite to endogenous ligand).

The dose-response relationship describes how drug effects change with different doses, showing that increasing dose can increase therapeutic response but also risk of toxicity. Potency refers to the drug concentration needed to produce 50% of maximum effect. Efficacy is the maximum response a drug can produce regardless of dose. Full agonists have intrinsic activity equal to 1, producing complete biological responses. Partial agonists have intrinsic activity between 0 and 1, producing submaximal responses even at high doses. This explains why different drugs acting on the same receptor type can produce different effects.

Agonists bind to receptors and produce a response (full or partial). Full agonists have high intrinsic activity (value of 1), while partial agonists have intermediate activity (0 < value < 1). Antagonists bind to receptors but produce no response (intrinsic activity = 0); they block agonists from binding. Potency is the amount of drug needed to produce a given effect (measured by ED50). Efficacy is the maximum effect a drug can produce regardless of dose.

In pharmacology, receptors are functional proteins with specific ligand-binding sites that mediate drug actions; agonists bind to receptors and activate them to produce maximal responses, antagonists bind to receptors without activating them and block agonist effects, partial agonists produce submaximal responses, and inverse agonists produce opposite effects compared to agonists; efficacy relates to the maximum response achievable, while potency relates to the drug dose required to produce 50% of the response (ED50).

Pharmacogenomics is the study of how genetic variations affect an individual's response to medications, influencing either pharmacokinetics (what the body does to the drug, such as metabolism via CYP enzymes) or pharmacodynamics (what the drug does to the body, such as drug-target binding). Genetic differences can result in varying metabolizer phenotypes (ultrarapid, intermediate, normal, poor, ultra-poor), which determine how effectively a person processes or responds to specific drugs. For example, CYP2C19 poor metabolizers cannot properly activate the blood thinner clopidogrel, increasing their risk of cardiac events, while certain MT-RNR1 gene variants can cause aminoglycoside antibiotics to damage human hearing cells instead of targeting bacteria.

Receptors and liver enzymes vary genetically among individuals, causing significant differences in drug responses. Polymorphisms cause some people to metabolize drugs much faster, requiring higher doses, while others metabolize slowly, causing standard doses to accumulate to toxic levels. This pharmacogenomic reality, studied since the late 20th century, explains why drugs work differently in different patients. Codeine exemplifies this: it's a prodrug converted by the CYP2D6 enzyme into morphine. Ultrarapid metabolizers convert codeine so quickly they can reach dangerous concentrations, while slow metabolizers barely convert it, making the analgesic ineffective. This understanding has transformed medicine from a one-size-fits-all approach to personalized treatment based on genetic profiles.

Pharmacogenomics studies how genetic variations affect drug metabolism and response. The cytochrome P450 enzyme system in the liver metabolizes many drugs, and genetic variations can significantly alter enzyme activity. Slow metabolizers may require higher drug doses for therapeutic effect, while fast metabolizers may experience reduced efficacy. Some substances like grapefruit juice can interact with these enzymes, affecting drug concentrations and potentially causing toxicity.

Pharmacogenomics (PGX) combines 'pharmaco' (drugs) and 'genomics' (genome study) to understand how genetic variations affect drug response. It focuses on drug metabolism, efficacy, and adverse reactions to create personalized medicine. Genetic variations include Single Nucleotide Polymorphisms (SNPs), structural variations (deletions, insertions, translocations), and copy number variations. Pharmacokinetics (ADME: absorption, distribution, metabolism, elimination) describes what the body does to drugs, while pharmacodynamics describes what drugs do to the body. The CYP2D6 gene on chromosome 22 produces an enzyme metabolizing 25% of clinical drugs and converting prodrugs like codeine to morphine. Point mutations in this gene can reduce enzymatic activity, causing variable drug responses—some patients metabolize drugs too quickly (reduced efficacy), others too slowly (increased toxicity).

Pharmacogenomics uses genetic information to understand how pharmacology interacts with an individual's body. Pharmacokinetics (ADME: Administration, Distribution, Metabolism, Excretion) describes how the body interacts with drugs, while pharmacodynamics describes how drugs interact with the body at the receptor level. Genetic variations in enzymes like PDE7B affect how quickly ester drugs are cleaved, determining individual responses to different compounds.